Kahkonen et al. reported the first in-human study of 68Ga-bombesin antagonist BAY867548, in which PET imaging successfully detected all dominant lesions with an accuracy of 83% for detection of the organ-confined disease and 70% sensitivity in the detection of lymph node metastases in human subjects with histologically confirmed prostate adenocarcinoma [26]. The gene discussed is GRP; the disease is prostate adenocarcinoma.